Effect of finasteride on the sensitivity of PSA for detecting prostate cancer: Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr, Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX

Autor: Smith, Joseph A.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2007 25(1):89-90

Prevalence of prostate cancer among men with a prostate-specific antigen level ⩽4.0 ng per milliliter: Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia, MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr., Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX. N Engl J Med 2004;350:2239–46

Autor: Smith, Joseph A., Jr.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2004 22(6):493-493

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Autor: Apolo AB; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Girardi DM; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Niglio SA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Nadal R; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Kydd AR; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Simon N; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Ley L; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Cordes LM; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Chandran E; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Steinberg SM; Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Lee S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Lee MJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Rastogi S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Sato N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Cao L; Molecular Targets Core, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Banday AR; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Boudjadi S; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Merino MJ; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Toubaji A; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Akbulut D; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Redd B; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Bagheri H; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Costello R; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Gurram S; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Agarwal PK; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Chalfin HJ; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Valera V; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Streicher H; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, MD., Wright JJ; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, MD., Sharon E; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, MD., Figg WD; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Parnes HL; Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD., Gulley JL; Center for Onco-Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Saraiya B; Genitourinary Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA., Quinn D; Division of Cancer Medicine and Blood Diseases, Department of Medicine, Genitourinary Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA., Stein MN; Genitourinary Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY., Lara PN; University of California Davis Comprehensive Cancer Center, Sacramento, CA., Bottaro DP; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, and the Comprehensive Cancer Center, Columbus, OH.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 01; Vol. 42 (25), pp. 3033-3046. Date of Electronic Publication: 2024 Jul 02.

PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.

Autor: Yilmaz EC; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Lin Y; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Belue MJ; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Harmon SA; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Phelps TE; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Merriman KM; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Hazen LA; Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD.; Department of Radiology, Clinical Center, NIH, Bethesda, MD., Garcia C; Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD.; Department of Radiology, Clinical Center, NIH, Bethesda, MD., Johnson L; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Lay NS; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Toubaji A; Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD., Merino MJ; Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD., Patel KR; Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD., Parnes HL; Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD., Law YM; Department of Radiology, Singapore General Hospital, Singapore., Wood BJ; Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD.; Department of Radiology, Clinical Center, NIH, Bethesda, MD., Gurram S; Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD., Choyke PL; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892., Pinto PA; Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD., Turkbey B; Molecular Imaging Branch, National Cancer Institute, NIH, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892.

Publikováno v: AJR. American journal of roentgenology [AJR Am J Roentgenol] 2024 Jan; Vol. 222 (1), pp. e2329964. Date of Electronic Publication: 2023 Sep 20.

A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.

Autor: Parsons JK; Department of Urology, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Pinto PA; National Cancer Institute, Bethesda, MD, USA., Pavlovich CP; Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA., Uchio E; Department of Urology, UC Irvine, Orange, CA, USA., Nguyen MN; Department of Urology, University of Southern California, Los Angeles, CA, USA., Kim HL; Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Gulley JL; National Cancer Institute, Bethesda, MD, USA., Sater HA; National Cancer Institute, Bethesda, MD, USA., Jamieson C; Department of Urology, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Hsu CH; University of Arizona Cancer Center, Tucson, AZ, USA., Wojtowicz M; National Cancer Institute, Bethesda, MD, USA., House M; National Cancer Institute, Bethesda, MD, USA., Schlom J; National Cancer Institute, Bethesda, MD, USA., Donahue RN; National Cancer Institute, Bethesda, MD, USA., Dahut WL; National Cancer Institute, Bethesda, MD, USA., Madan RA; National Cancer Institute, Bethesda, MD, USA., Bailey S; National Cancer Institute, Bethesda, MD, USA., Centuori S; University of Arizona Cancer Center, Tucson, AZ, USA., Bauman JE; University of Arizona Cancer Center, Tucson, AZ, USA., Parnes HL; National Cancer Institute, Bethesda, MD, USA., Chow HS; University of Arizona Cancer Center, Tucson, AZ, USA. Electronic address: schow@arizona.edu.

Publikováno v: European urology focus [Eur Urol Focus] 2023 May; Vol. 9 (3), pp. 447-454. Date of Electronic Publication: 2022 Dec 12.